Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038519
Status:
COMPLETED
Last Update Posted:
2006-07-28
First Post:
2002-05-31
Brief Title:
AmprenavirRitonavir or SaquinavirRitonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
An Open Label Phase II Study of AmprenavirRitonavir or SaquinavirRitonavir in HIV-Infected Subjects Following Failure With Kaletra LopinavirRitonavir as Their Second Protease Inhibitor
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to study the safety and efficacy of Amprenavirritonavir or saquinavirritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None